Evidence map›Paper›PMID 42599350›Full record

ArticleThe patient2026

Treatment Preferences for Relapsed/Refractory Mantle Cell Lymphoma Among Patients and Physicians in China: A Discrete Choice Experiment.

Jiachen Shao, Hui Peng, Li Zhou, Lei Liu, Xiao Ma, Xue Zhang, Zhiming Li, Shunping Li

Abstract read
PubMed Publisher
In one paragraph

Article in The patient, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiachen Shao *Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.
Hui Peng *Department of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.
Li ZhouLilly China Drug Development and Medical Affairs Center, Eli Lilly and Company, Shanghai, China.
Lei LiuLilly China Drug Development and Medical Affairs Center, Eli Lilly and Company, Shanghai, China.
Xiao MaLilly China Drug Development and Medical Affairs Center, Eli Lilly and Company, Shanghai, China.
Xue ZhangLilly China Drug Development and Medical Affairs Center, Eli Lilly and Company, Shanghai, China.
Zhiming LiDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. lizhm@sysucc.org.cn.
Shunping LiDepartment of Social Medicine and Health Management, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China. lishunping@sdu.edu.cn.ORCID http://orcid.org/0000-0001-8144-6220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma with a high relapse rate and poor treatment outcome. Treatment options for patients with relapsed/refractory (R/R) MCL remain limited and are associated with heterogeneous efficacy and safety profiles, especially in those previously treated with covalent Bruton tyrosine kinase inhibitors (cBTKi). This study aimed to elicit patients' and physicians' preferences for treatments for R/R MCL after cBTKi failure.

methodsFrom January to March 2025, a discrete choice experiment was conducted through face-to-face paper-based surveys in China. Respondents completed choice tasks comparing hypothetical treatments defined by seven attributes: duration of response (DOR), overall survival (OS), risk of serious infections, risk of cytokine-release syndrome (CRS), impact of chronic adverse events (AEs) on daily life, risk of discontinuation due to AEs, and treatment procedure. Mixed logit models were employed, and relative attribute importance (RAI) was calculated. Maximum acceptable risk analysis and scenario analysis were conducted to reveal the trade-offs respondents were willing to make. Preference heterogeneity was also explored through subgroup analysis.

resultsA total of 150 patients and 150 physicians were included in the analysis. Most patients (76.0%) had previously experienced failed cBTKi, and all physicians had experience in treating patients with R/R MCL in whom cBTKi had failed. OS (RAI = 35.3% [95% CI 29.2-41.3] for patients, 34.5% [95% CI 28.8-40.1] for physicians) was prioritized as the most important attribute by both patients and physicians, followed by impact of chronic AEs on daily life (25.2% [95% CI 20.9-29.5], 22.0% [95% CI 18.0-26.0]) and DOR (17.4% [95% CI 11.4-23.4], 19.0% [95% CI 13.0-25.0]). Patients and physicians were both willing to accept a higher risk of CRS in exchange for longer OS and DOR. Physicians also valued the risk of discontinuation due to AEs (RAI = 4.8% [95% CI 1.4-8.3]), while patients did not exhibit significant preferences for it.

conclusionOS emerged as the most important attribute for R/R MCL treatment after cBTKi for both patients and physicians. Preference differences were observed among patients and physicians. These insights may facilitate shared decision making and inform drug development and policy to enhance treatment adherence and improve health outcomes.

Identifiers

PMID42599350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.